Informed consent for BRCA1 and BRCA2 testing

Breast Disease

Volumn 10, Issue 1-2, 1998, Pages 99-114

  Rimer, Barbara K ^a   Sugarman, Jeremy ^a   Winer, Eric ^b   Bluman, Leslie G ^a   Lerman, Caryn ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER GENETICS; CANCER SUSCEPTIBILITY; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; INFORMED CONSENT; PRIORITY JOURNAL; REVIEW;

EID: 0031922167     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-1998-101-212     Document Type: Review

References (70)

1. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71.
2. Wooster R, Neuheusen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265:2088-2090.
3. National Advisory Council for Human Genome Research. Statement on use of DNA testing for presymptomatic identification of cancer risk. JAMA 1994; 271(10):785.
4. Task Force on Genetic Testing. Proposed recommendations of the task force on genetic testing. Department of Health and Human Services (National Institutes of Health), 1997.
5. Clayton EW, Hannig VL, Pfotenhauer JP, et al. Lack of interest by nonpregnant couples in population-based cystic fibrosis carrier screening. Am J Hum Genet 1996; 58:617-27.
6. Epstein CJ. 1996 ASHG Presidential Address: Toward the 21st century. Am J Hum Genet 1996; 60:1-9.
7. American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 1996; 14(5):1730-1736.
8. Pfeiffer N. Dr. Frederick Li speaks at MSKCC on "Opportunities for cancer control through genetics". Oncology Times 1997; 62-63.
9. Freedman TG. Editorial: Genetic susceptibility testing: a therapeutic illusion? Cancer 1997; 79(11):2063-2064.
10. Faden R, Beauchamp TL. A history and theory of informed consent. New York: Oxford University Press, 1986.
11. The Nuremberg Code. Washington DC: US Government Printing Office, 1948.
12. Jones JH. The Tuskegee Legacy: AIDS and the black community. Hastings Center Report 1992; 22(6):38-40.
13. Department of Health and Human Services, National Institutes of Health, Office for Protection from Research Risks. Code of Federal Regulations, Title 45, Part 46. "Protection of Human Subjects," 1994.
14. Schloendorff v. Society of New York Hospitals. 211 N.Y. 125, 105 N.E. 92, 1914.
15. Sugarman J, Powers M. How the doctor got gagged: the disintegrating right of privacy in the physician-patient relationship. JAMA 1991; 266(23):3323-3327.
16. Andrews LB. Commentary: Compromised consent: deficiences in the consent process for genetic testing. J Am Med Womens Assoc 1997; 52(1):39-42, 44.
17. Sharpe NF. Informed consent and Hntington's disease: a model for communication. Am J Med Genet 1994; 50:239-246.
18. American Society for Human Genetics. Statement of the American Society of Human Genetics: genetic testing for breast and ovarian cancer predisposition. Am J Hum Genet 1994; 55:i-iv.
19. National Action Plan on Breast Cancer National Human Genome Research Institute. Planning meeting on privacy and confidentiality in genetics research. June 9, 1997.
20. Geller G, Botkin JR, Green MJ, et al. Genetic testing for susceptibility to adult-onset cancer. JAMA 1997; 277(18):1467-1474.
21. Hoskins KF, Stopfer JE, Calzone KA, et al. Assessment and counseling for women with a family history of breast cancer: a guide for clinicians. JAMA 1996; 273(7):577-585.
22. Weinstein ND. Testing four competing theories of health protective behavior. Health Psychol 1993; 12:324-333.
23. Penman D, Holand J, Bahana G, et al. Physicians' perceptions. J Clin Oncol 1984; 2(7):849-855.
24. Geller G, Strauss M, Bernhardt BA, et al. "Decoding" informed consent: insights from women regarding breast cancer susceptibility testing. Hastings Center Report 1997; March-April: 28-33.
25. Lerman C, Croyle RT. Emotional and behavioral responses to genetic testing for susceptibility to cancer. Oncology 1996; 10(2):191-195,199.
26. McKinnon WC, Guttmacher AE, Greenblatt MS, et al. The familial cancer program of the Vermont Cancer Center: development of a cancer genetics program in a rural area. J Gen Counsel 1997; 6(2):131-145.
27. Evers-Kieboom G, Swerts A, Cassiman JJ, et al. The motivation of at-risk individuals and their partners in deciding for or against predictive testing for Huntington's disease. Clin Genet 1989; 34:29-40.
28. Kessler S, Field T, Worth L, et al. Attitudes of persons at risk for Huntington's disease toward predictive testing. Am J Med Genet 1987; 26:259-270.
29. Koller WC, Davenport J. Genetic testing for Huntington's disease. Ann Neurol 1984; 16:511-512.
30. Craufurd D, Dodge A, Kerzin-Storrar L, et al. Uptake of presymptomatic predictive testing for Huntington's disease. The Lancet 1989; 8663:603-605.
31. Quaid KA, Morris M. Reluctance to undergo predictive testing: The case of Huntington's disease. Am J Med Genet 1993; 45:41-45.
32. Tyler A, Ball D, Craufurd D. Presymptomatic testing for Huntington's disease in the United Kingdom. Br Med J, 1992; 304:1593-1596.
33. Tambor ES, Bernhardt BA, Chase GA, et al. Offering cystic fibrosis carrier screening to an HMO population: Factors associated with utilization. Am J Hum Genet 1994; 55:626-637.
34. Botkin JR, Alemagno S. Carrier screening for cystic fibrosis: A pilot study of the attitudes of pregnant women. Am J Public Health 1992; 82:723-25.
35. Williamson R, Allison MED, Bentley TJ, et al. Community attitudes to cystic fibrosis carrier testing in England: A pilot study. Prenat Diagn 1989; 9:727-734.
36. Tambor ES, Rimer BK, Strigo TS. Genetic testing for breast cancer susceptibility: awareness and interest among women in the general population. Am J Med Genet 1997; 68:43-49.
37. Chaliki H, Loader S, Levenkron JC, et al. Women's receptivity to testing for a genetic susceptibility to breast cancer. Am J Public Health 1995; 85(8 Pt 1):1133-1135.
38. Lerman C, Daly M, Masny M, et al. Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol 1994; 12(4):843-850.
39. Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996; 275:1885-1892.
40. Watson M, Lloyd SM, Eeles R, et al. Psychosocial impact of testing (by linkage) for the BRCA1 breast cancer gene: An investigation of two families in the research setting. Psycho-Oncology 1996; 5(3):233-239.
41. Holtzman NA, Faden R, Chwalow AJ, et al. Effect of informed parental consent on mother's knowledge of newborn screening. Pediatrics 1983; 72(6):807-812.
42. Sorenson JR, Swazey JP, Scotch NA. Effective genetic counseling: more informed clients. Birth defects: original article series. 1981; XVII:79-104.
43. Quaid KA, Brandt J, Faden RR, et al. Knowledge, attitude, and the decision to be tested for Huntington's disease. Clin Genet 1989; 36:431-438.
44. Lerman C, Lustbader E, Rimer B, et al. Effects of individualized breast cancer risk counseling: A randomized trial. J Natl Can Inst 1995; 87:286-292.
45. Wonderlick AL, Fine BA. Knowledge of breast cancer genetics among breast cancer patients and first-degree relatives of affected individuals. J Genet Counsel 1997; 6(2):111-129.
46. Lerman C, Biesecker B, Benkendorf JL, et al. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. J Natl Cancer Inst 1997; 89(2):148-157.
47. Patenaude AF, Rappeport JM, Smith BR. The physician's influence on informed consent for bone marrow transplantation. Theor Med 1986; 7:165-179.
48. Leonard CO, Chase GA, Childs B. Genetic counseling: a consumer's view. N Eng J Med 1972; 287:433-439.
49. Winer E, Borstelmann N, Bluman L, et al. Attitudes and risk perceptions of women with breast cancer considering testing for BRCA1/2 [Abstract 1937]. Presented at the 33rd Annual Meeting of the American Society of Clinical Oncology, Denver, CO, May 1997.
50. Audrain JA, Rimer BK, Cella D, et al. Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want? J Clin Oncol, in press.
51. Tessaro I, Borstelmann N, Regan K, et al. Genetic testing for susceptibility to breast cancer: findings from women's focus groups. J Women's Health 1997; 6(3):317-327.
52. Struewing JP, Lerman C, Kase RG, et al. Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epi, Biomark & Prev 1995; 4:169-173.
53. Daly MB, Lerman C. Ovarian cancer risk counseling: a guide for the practitioner. Oncology 1993; 7(11):27-34.
54. Berry DA, Parmigiani G, Sanchez J, et al. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Can Inst 1997; 89:227-238.
55. Schneider KA, Stopfer JE, Peters JA, et al. Complexities in cancer risk counseling: presentation of three cases. J Genet Counsel 1997; 6(2):147-167.
56. Garber DE, Schrag D. Testing for inherited cancer susceptibility. JAMA 1996; 275(24):1928-1929.
57. Burke W, Kahn MJ, Garber JE, et al. "First Do No Harm" also applies to cancer susceptibility testing. The Cancer Journal 1996; 250-252.
58. Warmuth MA, Sutton LM, Winer EP. A review of hereditary breast cancer: from screening to risk factor modification. Am J Med 1997; 102:407-415.
59. Hubbard R, Lewontin RC. Sounding Board: Pitfalls of Genetic Testing. N Eng J Med 1996; 334(18).
60. Geller G, Tambor ES, Chase GA, et al. Measuring physicians' tolerance for ambiguity and its relationship to their reported practices regarding genetic testing. Med Care 1993; 31(11):989-1001.
61. Geller G, Tambor ES, Chase GA, et al. Incorporation of genetics in primary care practice: will physicians do the counseling and will they be directive? Arch Fam Med 1993; 2:1119-1125.
62. Hall JG. 1995 ASHG Presidential Address: The challenges and opportunities of times of change. Am J Hum Genet 1996; 58:649-656.
63. Bloch M, Fahy M, Fox S, et al. Predictive testing for Huntington Disease: II. Demographic Characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates. Am J Med Genet 1989; 32:217-224.
64. Andrykowski MA, Munn RK, Studts JL. Interest in learning of personal genetic risk for cancer: a general population survey. Prev Med 1996; 25(5):527-536.
65. van Berkel D, Klinge I. Gene technology: also a gender issue. Views of Dutch informed women on genetic screening and gene therapy. Patient Educ Couns 1997; 31:49-55.
66. Croyle RT, Smith KR, Botkin JR, et al. Psychological responses to BRCA1 mutation testing: preliminary findings. Health Psychol 1997; 16(1):63-72.
67. DudokdeWit AC, Tibben A, Duivenvoorden HJ, et al. Psychological distress in applicants for predictive DNA testing for autosomal dominant, heritable, late onset disorders. J Med Genet 1997; 34:382-390.
68. Lerman C, Schwartz MD, Lin TH, et al. The influence of psychological distress on use of genetic testing for cancer risk. J Consult Clin Psychol 1997; 65(3):414-420.
69. Lynch HT, Lemon SJ, Durham C, et al. A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer 1997; 79(11):2219-2228.
70. Merz JF, Rischhoff B. Informed consent does not mean rational consent. J Leg Med 1990; 11:321-350.